Travere Therapeutics Soars with Filspari Approval

Travere Therapeutics Q1 earnings are scorching hot, with the first-ever FDA approval for Filspari in FSGS, a rare kidney disease affecting over thirty thousand US patients without nephrotic syndrome. This, coupled with record demand in IgA nephropathy, has led to a 88% year-over-year increase in Filspari sales, reaching $105 million. The FSGS launch was a success, with patient start forms and reimbursements approved within the first week. Nephrologists are excited about Filsparis potential for better kidney protection, and the phase three HARMONY study for pegtobatinase in classical homocystinuria is underway. The company is aiming for a $3 billion peak sales opportunity across both indications, with $352 million in cash to fuel growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/33291eec262ba22d